Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director | May 09, 2022 | May 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date May 09, 2022 · Filed May 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohn R. Treace and Ginger D. Treace JTTEN | 1,860,478 |
Reported balance
After 2022-05-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-05-09 · Sale · Disposed 37,312 · Balance 1,860,478 F1: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectJohn R. Treace and Ginger D. Treace JTTEN | 1,841,512 |
Reported balance
After 2022-05-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-09 · Sale · Disposed 18,966 · Balance 1,841,512 F1: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectJohn R. Treace and Ginger D. Treace JTTEN | 1,823,097 |
Reported balance
After 2022-05-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-05-09 · Sale · Disposed 18,415 · Balance 1,823,097 F1: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectJohn R. Treace and Ginger D. Treace JTTEN | 1,822,790 |
Reported balance
After 2022-05-09 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2022-05-09 · Sale · Disposed 307 · Balance 1,822,790 F1: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectAs Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 | 408,816 |
Reported balance
Holding disclosure · report date 2022-05-09 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 408,816 F6: The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2022 Filed May 11, 2022 17:59 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 307 | $15.97 | $4,901.72 |
DisclosureSEC source: 0001567619-22-010101 · doc1.xml · nonDerivative · entry 4 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 1,822,790 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 11, 2022 17:59 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 18,415 | $15.22 | $280,197.12 |
DisclosureSEC source: 0001567619-22-010101 · doc1.xml · nonDerivative · entry 3 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 1,823,097 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 11, 2022 17:59 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 18,966 | $14.20 | $269,387.37 |
DisclosureSEC source: 0001567619-22-010101 · doc1.xml · nonDerivative · entry 2 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 1,841,512 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 11, 2022 17:59 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 37,312 | $13.30 | $496,189.90 |
DisclosureSEC source: 0001567619-22-010101 · doc1.xml · nonDerivative · entry 1 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 1,860,478 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Feb 11, 2022 16:25 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 408,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003539 · doc1.xml · nonDerivative · entry 2 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 Disclosed balance after: 408,816 F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee. Read SEC document |
| September 07, 2021 Filed Feb 11, 2022 16:25 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 408,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003539 · doc1.xml · nonDerivative · entry 1 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 1,897,790 F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 427,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017470 · doc4.xml · derivative · entry 6 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 0 Underlying: Common Stock · 427,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 9,906 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017470 · doc4.xml · derivative · entry 5 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 9,906 Underlying: Common Stock · 9,906 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 401,250 | $17.00 | $6,821,250.00 |
DisclosureSEC source: 0000899243-21-017470 · doc4.xml · nonDerivative · entry 2 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 2,306,606 F2 · kind: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. F2 · price: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 427,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017470 · doc4.xml · nonDerivative · entry 1 TREACE JOHN R · CIK 0001185249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · John R. Treace and Ginger D. Treace JTTEN Disclosed balance after: 2,707,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.